Literature DB >> 12804850

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

Ayato Takada1, Sachiko Matsushita, Ai Ninomiya, Yoshihiro Kawaoka, Hiroshi Kida.   

Abstract

It has been known that influenza A virus infection induces a cross-protective immunity against infection by viruses with different subtypes of viral envelope proteins, hemagglutinin (HA) and neuraminidase (NA). This heterosubtypic immunity is generally mediated by cytotoxic T lymphocytes (CTL) reactive to specific epitopes in the viral internal proteins, such as nucleoprotein and matrix protein. By contrast, immunization with inactivated virus antigens has been thought to be unable to generate heterosubtypic immunity, since inactivated antigens do not usually induce CTL responses. However, we show that intranasal immunization with formalin-inactivated intact virus, but not ether-split vaccines, induced a broad spectrum of heterosubtypic protective immunity in mice. The protection may be mediated by the mucosal immune response, most likely secretory IgA antibodies to the viral proteins. This approach may overcome limitations in the efficacy of inactivated influenza vaccines and confer potent immunity to humans against viruses with new pandemic potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804850     DOI: 10.1016/s0264-410x(03)00234-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  73 in total

1.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine.

Authors:  Jürgen A Richt; Porntippa Lekcharoensuk; Kelly M Lager; Amy L Vincent; Christina M Loiacono; Bruce H Janke; Wai-Hong Wu; Kyoung-Jin Yoon; Richard J Webby; Alicia Solórzano; Adolfo García-Sastre
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.

Authors:  Alina C Boesteanu; Nadarajan S Babu; Margaret Wheatley; Elisabeth S Papazoglou; Peter D Katsikis
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

4.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

5.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.

Authors:  Toshihiro Sawai; Yasushi Itoh; Hiroichi Ozaki; Norikazu Isoda; Kiyoko Okamoto; Yoshitaka Kashima; Yoshihiro Kawaoka; Yoshihiro Takeuchi; Hiroshi Kida; Kazumasa Ogasawara
Journal:  Immunology       Date:  2008-01-16       Impact factor: 7.397

7.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

8.  Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination.

Authors:  Fu Shi Quan; Dae-Goon Yoo; Jae-Min Song; John D Clements; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

Review 9.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.